全胃切除术后单剂量地诺单抗治疗胃癌弥漫性骨转移后出现的持续性低钙血症
Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
作者信息
Iizumi Sakura, Shimoi Tatsunori, Nishikawa Tadaaki, Kitano Atsuko, Sasada Shinsuke, Shimomura Akihiko, Noguchi Emi, Yunokawa Mayu, Yonemori Kan, Shimizu Chikako, Fujiwara Yasuhiro, Tamura Kenji
机构信息
Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan.
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
出版信息
Intern Med. 2017 Nov 1;56(21):2879-2882. doi: 10.2169/internalmedicine.8908-17. Epub 2017 Sep 25.
Hypocalcemia is a significant adverse effect of denosumab. We herein report a case of prolonged hypocalcemia in a patient with multiple risk factors for hypocalcemia, including gastrectomy, increased bone turnover, and a poor performance status. Hypocalcemia developed after denosumab treatment for diffuse bone metastasis of gastric cancer, despite oral supplementation with vitamin D and calcium. To avoid serious prolonged hypocalcemia, a thorough assessment of the bone calcium metabolism is required before initiating denosumab treatment.
低钙血症是地诺单抗的一种显著不良反应。我们在此报告一例低钙血症患者出现长时间低钙血症的病例，该患者存在多种导致低钙血症的危险因素，包括胃切除术、骨转换增加和身体状况较差。尽管口服补充了维生素D和钙，但在使用地诺单抗治疗胃癌弥漫性骨转移后仍出现了低钙血症。为避免严重的长时间低钙血症，在开始使用地诺单抗治疗前需要对骨钙代谢进行全面评估。
Zotero 插件